IMPORTANCE OF SUFFICIENT TIME-POINTS FOR EFFICIENT PHARMACOKINETIC (PK) COMPARTMENTAL MODELING

Authors

  • TIRTHA NANDI Scientist, Clinical Pharmacology and Pharmacometrics, Alnylam Pharmaceuticals. 101 Main Street, 10th floor, Cambridge, MA 02142 https://orcid.org/0000-0002-6439-8543

DOI:

https://doi.org/10.22159/ijap.2023v15i1.46553

Keywords:

Compartmental modeling, pharmacokinetics (PK), classical PK models, IV bolus, clearance, volume of distribution, bioavailability

Abstract

Objective: Modeling and simulation are the two widely used terms, usually simultaneously mentioned in most PK discussions. There are several modeling strategies to model pharmacokinetic (PK) profiles. Compartmental modeling divides the body into different compartments based on the observed C-t profile and model comparison functions. Most C-t profiles are efficiently modeled using at max three compartments model (one, two, or three compartments). While there are many important applications of classical compartmental models, it emphasizes the importance of selecting the best model to explain the observed data. Therefore, initial data generation is very important. In many instances, insufficient data collection might not lead to the best model, which can be proved later costly by underpredicting or overpredicting PK parameters. This paper illustrates that adequate data collection can lead to correct model selection. 

Methods: Data was generated using the three-compartmental model's explicit equation for twenty-five simulated patients with 15% random variability. Generated data were fitted to different compartmental models using sufficient time points (case a) and without enough time points (case b). 

Results: In the case of a, generated data from three compartmental models was explained best by three compartmental models. In the case of b, the same data was presented better by two compartmental models. Finally, in the case of b, with sufficient time points, data generated from three compartmental models could be explained better by three compartmental models. 

Conclusion: With sufficient time points, the compartmental PK model can converge to an accurate one. Although almost all pharmacometricians know the importance of time points, there is no paper with a mathematical explanation of this incident. This paper will help the current and future pharmacometricians to help design efficient in vivo works.

Downloads

Download data is not yet available.

References

Alavijeh MS, Palmer AM. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. Curr Opin Investig Drugs. 2004;5:755-63.

Gibaldi M, Perrier D. Pharmacokinetics. Swarbrick J, editor. New York: Marcel Dekkar, Inc; 1982. 494 p.

Hedaya MA. Basic pharmacokinetics: CRC Press; 2012.

Dokoumetzidis A, Kalantzi L, Fotaki N. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Expert opinion on drug metabolism & toxicology. 2007;3(4):491-505.

Huang W, Lee SL, Lawrence XY. Mechanistic approaches to predicting oral drug absorption. The AAPS journal. 2009;11(2):217-24.

Lawrence XY, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. International journal of pharmaceutics. 1999;186(2):119-25.

Lin L, Wong H. Predicting oral drug absorption: mini review on physiologically-based pharmacokinetic models. Pharmaceutics. 2017;9(4):41.

Löbenberg R, Krämer J, Shah VP, Amidon GL, Dressman JB. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharmaceutical research. 2000;17(4):439-44.

Shargel L. Biopharmaceutics. Encyclopedia of Pharmaceutical Science and Technology, Fourth Edition: CRC Press; 2013. p. 195-210.

Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation: Springer; 2011.

Kim TH, Shin S, Shin BS. Model-based drug development: application of modeling and simulation in drug development. Journal of Pharmaceutical Investigation. 2018;48(4):431-41.

Rowland M, Lesko LJ, Rostami-Hodjegan A. Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making. CPT Pharmacometrics Syst Pharmacol. 2015;4(6):313-5. Epub 2015/08/01. doi: 10.1002/psp4.52. PubMed PMID: 26225258; PubMed Central PMCID: PMC4505824.

Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clinical Pharmacology & Therapeutics. 2011;89(2):259-67.

Zhao P, Rowland M, Huang SM. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clinical pharmacology & therapeutics. 2012;92(1):17-20.

Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016;6(5):430-40. Epub 2016/12/03. doi: 10.1016/j.apsb.2016.04.004. PubMed PMID: 27909650; PubMed Central PMCID: PMC5125732.

Dave VS, Patel MB. Method development and validation of difference UV spectrophotometric estimation of lafutidine in bulk and pharmaceutical dosage form. International Journal of Pharmacy and Pharmaceutical Sciences. 2012;4(4):284-7.

Sornsuvit C, Niamhun N, Luengpiansamut N, Sangsrijan S, Niwatananum W, Kaewvichit S, et al. Pharmacokinetics and bioequivalence studies of warfarin sodium 5 milligrams tablet in healthy Thai subjects. International Journal of Pharmacy and Pharmaceutical Sciences. 2015;7(3):219-22.

Iswandana R, Aisyah P, Syahdi RR. Prediction analysis of pharmacokinetic parameters of several oral systemic drugs using insilico method. International Journal of Applied Pharmaceutics. 2020:260-3.

Bruyere A, Decleves X, Bouzom F, Ball K, Marques C, Treton X, et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Molecular pharmaceutics. 2010;7(5):1596-607.

Ferl GZ, Theil FP, Wong H. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications. Biopharm Drug Dispos. 2016;37(2):75-92. Epub 2015/10/16. doi: 10.1002/bdd.1994. PubMed PMID: 26461173.

Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Journal of Pharmacokinetics and Pharmacodynamics. 2007;34(5):687-709. doi: 10.1007/s10928-007-9065-1.

Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, et al. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT Pharmacometrics Syst Pharmacol. 2016;5(10):516-31. Epub 2016/10/27. doi: 10.1002/psp4.12134. PubMed PMID: 27653238; PubMed Central PMCID: PMC5080648.

Li J, Wu J, Bao X, Honea N, Xie Y, Kim S, et al. Quantitative and mechanistic understanding of AZD1775 penetration across human blood–brain barrier in glioblastoma patients using an IVIVE–PBPK modeling approach. Clinical Cancer Research. 2017;23(24):7454-66.

Offman E, Edginton AN. A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide. J Pharmacokinet Pharmacodyn. 2015;42(2):135-50. Epub 2015/02/05. doi: 10.1007/s10928-015-9406-4. PubMed PMID: 25650156.

Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab Dispos. 2015;43(11):1823-37. Epub 2015/08/25. doi: 10.1124/dmd.115.065920. PubMed PMID: 26296709; PubMed Central PMCID: PMC4613950.

Wagner C, Zhao P, Pan Y, Hsu V, Grillo J, Huang SM, et al. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK. CPT: pharmacometrics & systems pharmacology. 2015;4(4):226-30.

Wong H, Chow TW. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins. J Pharm Sci. 2017;106(9):2270-5. Epub 2017/04/11. doi: 10.1016/j.xphs.2017.03.038. PubMed PMID: 28392453.

Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89(2):259-67. Epub 2010/12/31. doi: 10.1038/clpt.2010.298. PubMed PMID: 21191381.

Sakamoto Y, Ishiguro M, Kitagawa G. Akaike information criterion statistics. Dordrecht, The Netherlands: D Reidel. 1986;81.

Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. Journal of pharmacokinetics and biopharmaceutics. 1978;6(2):165-75.

Erratum: Blood Sample Collection in Small Laboratory Animals. J Pharmacol Pharmacother. 8. India2017. p. 153.

Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. Journal of Applied Toxicology: An International Journal. 2001;21(1):15-23.

Lundell A, Bergqvist D, Mattsson E, Nilsson B. Volume blood flow measurements with a transit time flowmeter: an in vivo and in vitro variability and validation study. Clinical physiology. 1993;13(5):547-57.

Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. Journal of pharmacology & pharmacotherapeutics. 2010;1(2):87-93. doi: 10.4103/0976-500X.72350. PubMed PMID: 21350616.

Chawla G, Bansal A. A means to address regional variability in intestinal drug absorption. Pharm tech. 2003;27(2):50-68.

Dimitrov S, Detroyer A, Piroird C, Gomes C, Eilstein J, Pauloin T, et al. Accounting for data variability, a key factor in in vivo/in vitro relationships: application to the skin sensitization potency (in vivo LLNA versus in vitro DPRA) example. Journal of Applied Toxicology. 2016;36(12):1568-78.

Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica. 2006;36(6):473-97.

Pham LL, Watford SM, Pradeep P, Martin MT, Thomas RS, Judson RS, et al. Variability in in vivo studies: Defining the upper limit of performance for predictions of systemic effect levels. Computational Toxicology. 2020;15:100126.

Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, et al. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences. 2021;162:105812.

Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89-295. Epub 2009/06/12. doi: 10.1080/03602530902843483. PubMed PMID: 19514967.

Published

21-11-2022

How to Cite

NANDI, T. (2022). IMPORTANCE OF SUFFICIENT TIME-POINTS FOR EFFICIENT PHARMACOKINETIC (PK) COMPARTMENTAL MODELING. International Journal of Applied Pharmaceutics, 15(1). https://doi.org/10.22159/ijap.2023v15i1.46553

Issue

Section

Original Article(s)